Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Spotted Fever Treatment Market size is projected to grow at substantial growth rate during the forecast period i.e., between 2025-2037.
The growth of the market can be primarily attributed to the increasing prevalence of bacterial infections, coupled with improper maintenance of hygiene in homes and nearby surroundings. According to the Centers for Disease Control and Prevention (CDC), as of 2019, antibiotic resistant fungi and bacteria cause more than 2.8 million infections and 35,000 deaths in the United States each year. Along with these, growing trend of travel and forest tourism, especially in North and South American countries, is assessed to lead to high exposure of a large number of people to several different species of ticks, which are the only cause of spotted fever. This is in turn is predicted to drive robust growth to the growth in the forthcoming years. Furthermore, rise in healthcare spending is projected to offer abundant opportunities to market players in the near future.
Spotted Fever Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Prevalence of Bacterial Infections
- Growing Trend of Travel and Forest Tourism
Challenges
- Lack of Appropriate Treatment Options in Lower Economic Regions
Spotted Fever Treatment Segmentation
The market is segmented by treatment into doxycycline, chloramphenicol, and others, out of which, the doxycycline segment is anticipated to hold the largest share in the global spotted fever treatment market. This can be accounted to the fact that using antibiotics other than doxycycline is associated with higher risk of fatal outcome from spotted fever, and its excellent effectiveness in preventing severe complications from the illness. Apart from this, when treated with this drug, fever generally subsides within 24-48 hours, which is expected to augment its sales in the years to come. Additionally, on the basis of end user, the hospitals segment is evaluated to grab the largest share over the forecast period owing to the high preference of patients to be treated under the supervision of a professional in a hospital facility.
Our in-depth analysis of the global spotted fever treatment market includes the following segments
|
By Treatment |
|
|
By End User |
|
|
By Drug Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportSpotted Fever Treatment Industry - Regional Synopsis
On the basis of geographical analysis, the global spotted fever treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. North America industry is estimated to dominate majority revenue share by 2037, backed by high number of cases of patients with spotted fever, and presence of climatic conditions favoring the occurrence of tickborne diseases. As per another report by the CDC, the total cases of spotted fever in the U.S. have risen in the last 2 decades, from 495 cases in 2000, to 6,248 cases in 2017. However, 5,544 and 5,207 cases of the disease were reported in 2018 and 2019 respectively.
In addition, large healthcare expenditure is also a major factor projected to boost the growth of the market in the coming years. Moreover, the market in Latin America is also anticipated to grab a sizeable share during the forecast period ascribing to the growing prevalence of tick-based infections and improper maintenance of cleanliness in various parts of the region.
Companies Dominating the Landscape
- Pfizer, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Sun Pharmaceutical Industries, Inc.
- Novartis AG
- GlaxoSmithKline Plc
- Johnson & Johnson Services, Inc.
- F-Hoffman La Roche AG
- Bristol-Myers Squibb Company
- Merck & Co.
- Eli Lilly and Company
- AbbVie Inc.
Author Credits: Radhika Pawar
- Report ID: 3652
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT
